Form 6-K KAMADA LTD For: Jul 13

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

For the Month of July 2026

 

Commission File Number 001-35948

 

Kamada Ltd.

(Translation of registrant’s name into English)

 

2 Holzman Street
Science Park, P.O. Box 4081
Rehovot 7670402
Israel
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

 

 

This Form 6-K is being incorporated by reference into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267 and 333-265866.

 

The following exhibit is attached:

 

99.1

Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 13, 2026	KAMADA LTD.
	By:	/s/ Nir Livneh
		Nir Livneh Vice President General Counsel and Corporate Secretary

 

 

EXHIBIT INDEX

 

EXHIBIT NO.		DESCRIPTION
99.1		Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting

 

 

ATTACHMENTS / EXHIBITS

KAMADA HIGHLIGHTS CYTOGAM STUDY RESULTS PRESENTED AT THE 2026 ISHLT ANNUAL MEETING

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies
• Mintos launches free ETF investing, starting from €1
• Kamada shares CYTOGAM study data from 2026 ISHLT meeting